The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 19, 2007, Pages 5300-5309

  Hamblett, Christopher L ^a   Methot, Joey L ^a   Mampreian, Dawn M ^a   Sloman, David L ^a   Stanton, Matthew G ^a   Kral, Astrid M ^a   Fleming, Judith C ^a   Cruz, Jonathan C ^a   Chenard, Melissa ^a   Ozerova, Nicole ^a   Hitz, Anna M ^a   Wang, Hongmei ^a   Deshmukh, Sujal V ^a   Nazef, Naim ^a   Harsch, Andreas ^a   Hughes, Bethany ^a   Dahlberg, William K ^a   Szewczak, Alex A ^a   Middleton, Richard E ^a   Mosley, Ralph T ^a   Secrist, J Paul ^a   Miller, Thomas A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Benzamides; Epigenetics; Histone acetylation; Histone deacetylases; Nicotinamides

Indexed keywords

4 N ACETYLDINALINE; 6 AMINONICOTINAMIDE; BENZAMIDE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MGCD 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL)NICOTINAMIDE; NICOTINAMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CELL STRAIN HCT116; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHARMACODYNAMICS; T CELL LYMPHOMA; XENOGRAFT;

6-AMINONICOTINAMIDE; ANIMALS; AREA UNDER CURVE; BENZAMIDES; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; DOGS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HALF-LIFE; HISTONE DEACETYLASES; HUMANS; ISOENZYMES; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 34548563726     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.023     Document Type: Article

References (50)

1. Feinberg A.P., and Vogelstein B. Nature 301 (1983) 89
2. Holliday R. Science 238 (1987) 163
3. Jones P.A., and Baylin S.B. Nat. Rev. Genet. 3 (2002) 415
4. Kouzarides T. EMBO J. 19 (2000) 1176
5. Grozinger C.M., and Schreiber S.L. Chem. Biol. 9 (2002) 3
6. Urnov F.D., and Wolffe A. Emerg. Ther. Targets 4 (2000) 665
7. Ng H.H., and Bird A. Trends Biochem. Sci. 25 (2000) 121
8. Strahl B.D., and Allis C.D. Nature 403 (2000) 41
9. Jenuwein T., and Allis C.D. Science 293 (2001) 1074
10. Monneret C. Eur. J. Med. Chem. 40 (2005) 1
11. Kelly W.K., O' Connor O.A., and Marks P.A. Expert Opin. Invest. Drugs 11 (2002) 1695
12. Miller T.A., Witter D.J., and Belvedere S. J. Med. Chem. 46 (2003) 5097
13. Miller T.A. Expert Opin. Ther. Pat. 14 (2004) 791
14. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 10014
15. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Curr. Opin. Oncol. 13 (2001) 477
16. Marks P.A., Rifkind R.A., Richon V.M., and Breslow R. Clin. Cancer Res. 7 (2001) 759
17. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Nat. Rev. Cancer 1 (2001) 194
18. Meinke P.T., and Liberator P. Curr. Med. Chem. 8 (2001) 211
19. Marks P.A., Miller T., and Richon V.M. Curr. Opin. Pharmacol. 3 (2003) 344
20. Curtin M., and Glaser K. Curr. Med. Chem. 10 (2003) 2373
21. Marks P.A., and Breslow R. Nat. Biotechnol. 25 (2007) 84
22. Kelly W.K., O'Connor O.A., and Marks P.A. Expert Opin. Invest. Drugs 11 (2002) 1695
23. Jenuwein T., and Allis C.D. Science 293 (2001) 1074
24. Suzuki T., Ando T., Tsuchiya K., Fukazawa N., Saito A., Mariko Y., Yamashita T., and Nakanishi O. J. Med. Chem. 42 (1999) 3001
25. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., and Nakanishi O. Proc. Natl. Acad. Sci. 96 (1999) 4592
26. Jaboin J., Wild J., Hamidi H., Khanna C., Kim C.J., Robey R., Bates S.E., and Thiele C.J. Cancer Res. 62 (2002) 6108
27. El-Beltagi H.M., Martens A.C.M., Lelieveld P., Haroun E.A., and Hagenbeek A. Cancer Res. 53 (1993) 3008
28. Loprevite M., Tiseo M., Grossi F., Scolaro T., Semino C., Pandolfi A., Favoni R., and Ardizzoni A. Oncol. Res. 15 (2005) 39
29. Foster B.J., Jones L., Wiegand R., Lorusso P.M., and Corbett T.H. Invest. New Drugs 15 (1997) 187
30. Delorme, D.; Woo, S. H.; Vaisburg, A.; Moradel, O.; Leit, S.; Raeppel, S.; Frechette, S.; Bouchain, G. PCT Int. Appl. 2003, WO 2003024448.
31. Siu, L. L; Carducci, M.; Pearce, L.; Maclean, M.; Sullivan, R.; Li, Z.; Kalita, A.; Chen, E. X.; Pili, R.; Longstreth, J.; Martell, R. E.; Reid, G. K. Abstracts of Posters, C77: Phase I Study of Isotype Selective Histone Deactylase (HDAC) Inhibitor MGCD0103 Given as Three-Times Weekly Oral Dose in Patients (pts) with Advanced Solid Tumors, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, Pennsylvania, November 14-18, 2005.
32. 2, and 0.1 mg/mL BSA. HDAC enzymatic activities were determined by the following procedure: 3× serial dilutions of a 10 mM solution of inhibitor were performed in DMSO followed by a 20× dilution into Assay buffer. 20 μl HDAC was preincubated with 5 μL diluted compound at RT for 10 min. The reaction was initiated by the addition of 25 μL of the appropriate substrate (HDACs 1, 2, 3, and 6: fluor-de-Lys substrate KI-104; HDAC8: fluor-de-Lys HDAC8 substrate KI-178), incubated 15 (HDAC8) or 60 (HDACs 1, 2, 3, and 6) minutes at 37 °C, before adding 50 μL of the appropriate development solution. The development solution for HDACs 1, 2, 3, and 6 was 167×-diluted 20× Developer Concentrate (BIOMOL: KI-105) plus 10 μM SAHA. For HDAC8, the development solution was 100×-diluted 5× Developer Concentrate (BIOMOL: KI-176) plus 10 μM SAHA. The assay was read in a VictorV plate reader (Perkin-Elmer, Wellesley, MA) at Ex 360 nm/Em 460 nm. The final substrate concentration was 30 μM and final HDAC concentrations in the reaction were 1 nM for HDACs 1, 3, and 6), 2 nM for HDAC2, and 15 nM for HDAC8. Carboxy-terminal FLAG-tagged human HDACs 1, 2, 3 (co-expressed with the domain of SMRT), and 6 were overexpressed in mammalian cells and affinity purified using an anti-Flag antibody matrix, eluted from the matrix with 100 μg/mL of a competing FLAG peptide in 20 mM Tris-Cl, pH 8.0, 150 mM NaCl, 10% glycerol, and protease inhibitor cocktail (Roche cat. # 1836153).
33. Seto C.T., Mathias J.P., and Whitesides G.M. J. Am. Chem. Soc. 115 (1993) 1321
34. 2, viable cells were quantitated using Vialight Plus (Cambrex) according to manufacturer's instructions.
35. + 446.2, exp. 446.2.
36. Heltweg B., Dequiedt F., Marshall B.L., Brauch C., Yoshida M., Nishino N., Verdin E., and Jung M. J. Med. Chem. 47 (2004) 5235
37. Curtin M.L. Expert Opin. Ther. Pat. 12 (2002) 1375
38. HDAC8 crystal structure (1T64). Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., Tang J., Sang B.-C., Verner E., Wynands R., Leahy E.M., Dougan D.R., Snell G., Navre M., Knuth M.W., Swanson R.V., McRee DE., and Tari L.W. Structure 12 (2004) 1325
39. HDAC8 crystal structure (1T64). Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., Tang J., Sang B.-C., Verner E., Wynands R., Leahy E.M., Dougan D.R., Snell G., Navre M., Knuth M.W., Swanson R.V., McRee DE., and Tari L.W. Structure 12 (2004) 1325
40. HDLP crystal structure (1C3S). Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Nature 401 (1999) 188
41. An alignment of the two crystal structures and the amino acid sequence for hHDAC1 (retrieved from SwissProt, accession ID: Q13547) was accomplished using the sequence/structure alignment tools in MOE (Chemical Computing Group, Montreal, Canada). This alignment was then used in Quanta/Modeler5 (Accelrys, San Diego, CA, USA) to generate a set of homology models. That with the least number of violations was further energy minimized using CHARMm 200 steps steepest descents without the catalytic Zn or any waters present:. Sánchez R., and Sali A. Comparative protein structure modeling. In: Webster D.M. (Ed). Protein Structure Prediction: Methods and Protocols Vol. 143 (2000), Humana Press, New Jersey 97-129
42. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., and Karplus M. J. Comp. Chem. 4 (1983) 187
43. Wang D.-F., Helquist P., Wiech N.L., and Wiest O. J. Med. Chem. 48 (2005) 6936
44. The 150 conformers were generated and energy minimized using MMFFs with a distance-dependent dielectric of 2r:. Crippen C.M., and Havel T.F. Distance Geometry and Molecular Conformation. In: Bawden D. (Ed). Chemometrics Research Studies Series (1988), Research Studies Press, Wiley, New York
45. Halgren T.A. J. Comp. Chem. 20 (1999) 720
46. During the course of energy minimization within the context of the enzyme model, only slight differences in the presentation of the co-minimizing residues (those within 5 Å of the inhibitor) were noted between the starting and final enzyme structure. The catalytic Zn and chelating residues were virtually unchanged during the minimization process.
47. 2 for 24 hours with either 0.2% DMSO or increasing concentrations of 7i dissolved in DMSO (final DMSO concentration = 0.2%). Whole cell lysates were made by disrupting cell membranes with 2% deoxycholate followed by sonication. Using these HCT116 lysates as antigen, H2BK5 acetylation was quantified using an indirect ELISA and normalized to total H2B levels obtained using a second indirect ELISA. Primary antibodies used were rabbit anti-acetylated H2BK5 (Cell Signaling) and sheep anti-histone H2B (Abcam). Goat anti-rabbit IgG HRP (Bio-Rad) and rabbit anti-sheep-HRP (Jackson ImmunoResearch) were used as secondary antibodies, respectively. TMB substrate (Pierce) was used for detection with absorbance read at 450 nm.
48. Yoo C.B., and Jones P.A. Nat. Rev. Drug Disc. 5 (2006) 37
49. Bolden J.E., Peart M.J., and Johnstone R.W. Nat. Rev. Drug. Disc. 5 (2006) 769
50. Moradei O., Maroun C.R., Paquin I., and Vaisburg A. Curr. Med. Chem.: Anti-Cancer Agents 5 (2005) 529